Benchmark Initiates Coverage On Intensity Therapeutics with Speculative Buy Rating, Announces Price Target of $12
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Robert Wasserman has initiated coverage on Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy rating and a price target of $12.
July 18, 2023 | 10:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intensity Therapeutics has been given a Speculative Buy rating by Benchmark with a price target of $12.
The Speculative Buy rating from Benchmark indicates a positive outlook for Intensity Therapeutics. The price target of $12 suggests that the analyst believes there is potential for significant upside in the stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100